Divi's Laboratories Limited (DIVISLAB) — Board Meeting | 3 February 2025(2 announcements)

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Board Meeting 🟡 Notable Neutral 📄 PDF

Divi's Laboratories reported a 25.7% YoY jump in consolidated total income to ₹2401 crores for Q3 FY25, with profit before tax rising 48.5% to ₹726 crores and profit after tax up 64.4% to ₹589 crores. The board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, and reappointed Dr. Kiran S. Divi as Whole-time Director and CEO for five years effective April 1, 2025, subject to shareholder approval. The company highlighted new commercial operations at its Kakinada project and tax benefit elections under Section 115BAA.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

Divi's Laboratories announced on February 3, 2025, that Manoranjan Jasti and Suresh Ravi were designated as Senior Management Personnel effective immediately, following board approval of their appointment terms. The filing confirms their current roles — Jasti as Chief Information Officer and Ravi as Deputy General Manager (Engineering) — and outlines their expanded responsibilities in IT strategy and manufacturing operations. This structural reinforcement aims to strengthen operational continuity and leadership depth within the company.

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

📊 More DIVISLAB filings

See all DIVISLAB filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DIVISLAB — Free

Free account · 2 AI queries/day